New drug compound could tackle major life-limiting kidney disease
June 18, 2019
University of Sheffield
Scientists are developing a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure.
Scientists from the University of Sheffield are part of an international collaboration to develop a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure.
Working with Glasgow-based biotech company Mironid and colleagues in the US, the Sheffield researchers have carried out successful laboratory tests of a compound developed by Mironid to treat autosomal dominant polycystic kidney disease (ADPKD), a hereditary, progressive disease which affects over 60,000 people in the UK and around 12 million people worldwide.